Abstract
Pharmacodynamics is the action the drug has on the body. The main elements connected with it are the plasma concentration, protein binding, and the receptor affinity. Half-life in plasma is the duration in which the drug level falls to 50%. Pharmacokinetics is how the drug travels in the body over time and their variations in concentration across time in blood. So far we have dealt with considerable details both these aspects of insulin in the body tissues and cells. Here these functions will be more fully understood against the backdrop of pharmacotherapy of insulin and its pharmacokinetics from a different perspective in all kinds of situations in diabetes.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Notes
- 1.
In attempts to minimize the fears associated with insulin administration for the first time, a regime called BIDS is sometimes used. It spells out as bedtime (intermediate) insulin daytime sulfonylurea. Single NPH rarely is effective and lasts for a short time if at all. It is better to start with two injections of intermediate-acting variety 12Â h apart if insulin regime becomes necessary. Such regimes of insulin combined with OHAs are not discussed here.
References
Insulin pharmacology Lutz Heinemann, 2002.
Home PD. The pharmacokinetics and pharmacodynamics of rapid-acting insulin analogues and their clinical consequences. Diabetes Obes Metab. 2012;14:780–8.
Dailey G, Rosenstock J, Moses RG, Ways K. Insulin glulisine provides improved glycemic control in patients with type 2 diabetes. Diabetes Care. 2004;27:2363–8.
Meyer C, Boron A, Plummer E, Voltchenok M, Vedda R. Glulisine versus human regular insulin in combination with glargine in noncritically ill hospitalized patients with type 2 diabetes: a randomized double-blind study. Diabetes Care. 2010;33:2496–501; http://care.diabetesjournals.org on 30 Aug 2010.
Chawla M, Malve H, Shah H, Shinde S, Bhoraskar A. Safety of intravenous insulin Aspart compared to regular human insulin in patients undergoing ICU monitoring post cardiac surgery: an Indian experience. J Diabetes Metab Disord. 2015;14:20.
Lepore M, Pampanelli S, Fanelli C, et al. Pharmacokinetics and pharmacodynamics of subcutaneous injection of long-acting human insulin analog glargine, NPH insulin, and ultralente human insulin and continuous subcutaneous infusion of insulin lispro. Diabetes. 2000;49:2142–8.
Rys P, Wojciechowski P, Rogoz-Sitek A, Niesyczyński G, Lis J, Syta A, Malecki MT. Systematic review and meta-analysis of randomized clinical trials comparing efficacy and safety outcomes of insulin glargine with NPH insulin, premixed insulin preparations or with insulin detemir in type 2 diabetes mellitus. Acta Diabetol. 2015;52(4):649–62, Published online: 14 Jan 2015.
Home P, Bartley P, Russell-Jones D, et al. Study to evaluate the administration of detemir insulin efficacy, safety and suitability (STEADINESS) study group. Insulin detemir offers improved glycemic control compared with NPH insulin in people with type 1 diabetes: a randomized clinical trial. Diabetes Care. 2004;27:1081–7.
Russell-Jones D, Simpson R, Hylleberg B, Draeger E, Bolinder J. Effects of QD insulin detemir or neutral protamine Hagedorn on blood glucose control in patients with type I diabetes mellitus using a basal-bolus regimen. Clin Ther. 2004;26:724–36.
Pieber TR, Draeger E, Kristensen A, Grill V. Comparison of three multiple injection regimens for type 1 diabetes: morning plus dinner or bedtime administration of insulin detemir vs. morning plus bedtime NPH insulin. Diabet Med. 2005;22:850–7.
Vague P, Selam JL, Skeie S, et al. Insulin detemir is associated with more predictable glycemic control and reduced risk of hypoglycemia than NPH insulin in patients with type 1 diabetes on a basal-bolus regimen with premeal insulin aspart. Diabetes Care. 2003;26:590–6.
De Leeuw I, Vague P, Selam JL, et al. Insulin detemir used in basal-bolus therapy in people with type 1 diabetes is associated with a lower risk of nocturnal hypoglycaemia and less weight gain over 12 months in comparison to NPH insulin. Diabetes Obes Metab. 2005;7:73–82.
Standl E, Lang H, Roberts A. The 12-month efficacy and safety of insulin detemir and NPH insulin in basal-bolus therapy for the treatment of type 1 diabetes. Diabetes Technol Ther. 2004;6:579–88.
Bott S, Tusek C, Jacobsen LV, et al. Insulin detemir under steady-state conditions: no accumulation and constant metabolic effect over time with twice daily administration in subjects with type 1 diabetes. Diabet Med. 2006;23:522–8.
Kølendorf K, Ross GP, Pavlic-Renar I, et al. Insulin detemir lowers the risk of hypoglycaemia and provides more consistent plasma glucose levels compared with NPH insulin in type 1 diabetes. Diabet Med. 2006;23:729–35.
Hermansen K, Fontaine P, Kukolja KK, Peterkova V, Leth G, Gall MA. Insulin analogues (insulin detemir and insulin aspart) versus traditional human insulins (NPH insulin and regular human insulin) in basal-bolus therapy for patients with type 1 diabetes. Diabetologia. 2004;47:622–9.
Fajardo Montañana C, Hernández Herrero C, Rivas Fernández M. Less weight gain and hypoglycaemia with once-daily insulin detemir than NPH insulin in intensification of insulin therapy in overweight type 2 diabetes patients: the PREDICTIVE BMI clinical trial. Diabet Med. 2008;25:916–23.
Hermansen K, Davies M, Derezinski T, Martinez Ravn G, Clauson P, Home P. A 26-week, randomized, parallel, treat-to-target trial comparing insulin detemir with NPH insulin as add-on therapy to oral glucose lowering drugs in insulin-naive people with type 2 diabetes. Diabetes Care. 2006;29:1269–74.
Philis-Tsimikas A, Charpentier G, Clauson P, Ravn GM, Roberts VL, Thorsteinsson B. Comparison of once-daily insulin detemir with NPH insulin added to a regimen of oral antidiabetic drugs in poorly controlled type 2 diabetes. Clin Ther. 2006;28:1569–81.
Scholtz HE, Pretorius SG, Wessels DH, Becker RH. Pharmacokinetic and glucodynamic variability: assessment of insulin glargine, NPH insulin and insulin ultralente in healthy volunteers using a euglycaemic clamp technique. Diabetologia. 2005;48:1988–95.
Heise T, Nosek L, Rønn BB, et al. Lower within-subject variability of insulin detemir in comparison to NPH insulin and insulin glargine in people with type 1 diabetes. Diabetes. 2004;53:1614–20.
Becker RH, Frick AD, Teichert L, et al. Fluctuation and reproducibility of exposure and effect of insulin glargine in healthy subjects. Diabetes Obes Metab. 2008;10:1105–13.
Author information
Authors and Affiliations
Rights and permissions
Copyright information
© 2019 Springer Nature Singapore Pte Ltd.
About this chapter
Cite this chapter
Kelkar, S., Muley, S., Ambardekar, P. (2019). Insulin Pharmacodynamics, Pharmacokinetics, and Insulin Regimens. In: Towards Optimal Management of Diabetes in Surgery. Springer, Singapore. https://doi.org/10.1007/978-981-13-7705-1_11
Download citation
DOI: https://doi.org/10.1007/978-981-13-7705-1_11
Published:
Publisher Name: Springer, Singapore
Print ISBN: 978-981-13-7704-4
Online ISBN: 978-981-13-7705-1
eBook Packages: MedicineMedicine (R0)